April 21st 2024
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Gaining More Benefit from Ruxolitinib for Patients With Polycythemia Vera, Other MPNs
September 28th 2016Since its approval 5 years ago, ruxolitinib (Jakafi) continues to drastically change the treatment landscape and quality of life of patients with myeloproliferative neoplasms (MPNs), including a subset of patients with the bone marrow neoplasm, polycythemia vera (PV).
Read More
Ruxolitinib Beats Out Best Available Therapy in Polycythemia Vera
September 27th 2016Follow up at 80 weeks to the open-label phase III RESPONSE trial confirmed the benefit of ruxolitinib over best available therapy (BAT) in the treatment of patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.
Read More
Researchers Join Forces to Accelerate Progress in Pediatric High-Grade Gliomas
September 20th 2016Goals of "Project Impact: A Campaign to Defeat Pediatric Brain Tumors" include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.
Read More
Molecular, Genetic Studies Provide New Insights Into MDS/MPN
September 16th 2016As molecular and genetic studies have provided new insights into myelodysplastic and myeloproliferative neoplasms (MDS/MPN), diagnostic criteria and therapeutic strategies for the diseases continue to evolve.
Read More
Ruxolitinib Improves Overall Survival in Myelofibrosis
June 14th 2016Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib (Jakafi) confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis. The JAK-2 inhibitor resulted in durable reductions in splenomegaly and improved overall survival, with patients experiencing no new or unexpected adverse events as a result of the long-term treatment.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Underused Ovarian Cancer Treatment Improves Overall Survival
August 7th 2015Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment
Read More
Cabozantinib (Cometriq) Improves PFS and OS in Patients With mRCC
July 20th 2015Results from the phase III METEOR study showed that treatment with cabozantinib (Cometriq) improved progression-free survival (PFS) and overall survival (OS) compared with everolimus (Afinitor) in previously treated patients with metastatic renal cell carcinoma (mRCC).
Read More
Novel JAK Inhibitor Reduces Spleen Volume and Symptoms in Myelofibrosis
May 31st 2015Compared with best available therapy, the novel JAK2 inhibitor pacritinib demonstrated significantly better outcomes in spleen volume reduction and symptom control when administered to patients with myelofibrosis.
Read More
Upfront Fulvestrant Improves OS Compared With Anastrozole in HR-Positive MBC
December 13th 2014Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer. These findings from the phase II FIRST trial were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Neratinib Shows Promise for HER2-Positive Breast Cancer in I-SPY 2 Trial
April 10th 2014The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer.
Read More
Imetelstat Demonstrates Promising Efficacy in Myelofibrosis
December 11th 2013An investigator reported at the 55th annual meeting of the American Society of Hematology (ASH) that imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.
Read More